Evaluation of plasmodium vivax genotyping markers for molecular monitoring in clinical trials

Journal of Infectious Diseases

Volumn 199, Issue 7, 2009, Pages 1074-1080

  Koepfli, Cristian ^a   Mueller, Ivo ^b   Marfurt, Jutta ^a,c   Goroti, Mary ^b   Sie, Albert ^b   Oa, Olive ^b   Genton, Blaise ^a   Beck, Hans Peter ^a   Felger, Ingrid ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; CHLOROQUINE; FANSIDAR; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 1F1; MEROZOITE SURFACE PROTEIN 1F3; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3ALPHA; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; PARASITE ANTIGEN; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; MICROSATELLITE DNA; PROTOZOAL PROTEIN;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MICROSATELLITE MARKER; MOLECULAR CLONING; PAPUA NEW GUINEA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SUPERINFECTION; ALLELE; ANIMAL; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GENETIC MARKER; GENETICS; PARASITOLOGY;

ALLELES; ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; GENE FREQUENCY; GENETIC MARKERS; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; MALARIA, VIVAX; MICROSATELLITE REPEATS; PAPUA NEW GUINEA; PLASMODIUM VIVAX; PROTOZOAN PROTEINS;

EID: 65549115512     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597303     Document Type: Article

References (33)

1. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol 2006; 22:353-8.
2. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001; 64:97-106.
3. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:79-87.
4. Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol 2007; 23:533-9.
5. Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77:984-91.
6. Genton B, D'Acremont V, Rare L, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 2008; 5:e127.
7. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol 2006; 22:353-8.
8. Muller I, Bockarie M, Alpers M, Smith T. The epidemiology of malaria in Papua New Guinea. Trends Parasitol 2003; 19:253-9.
9. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195:927-33.
10. Zakeri S, Barjesteh H, Djadid ND. Merozoite surface protein-3alpha is a reliable marker for population genetic analysis of Plasmodium vivax. Malar J 2006; 5:53.
11. Imwong M, Pukrittayakamee S, Gruner AC, et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 2005; 4:20.
12. Kim JR, Imwong M, Nandy A, et al. Genetic diversity of Plasmodium vivax in Kolkata, India. Malar J 2006; 5:71.
13. Snewin VA, Khouri E, Wattavidanage J, et al. A new polymorphic marker for PCR typing of Plasmodium vivax parasites. Mol Biochem Parasitol 1995; 71:135-8.
14. Imwong M, Pukrittakayamee S, Looareesuwan S, et al. Plasmodium vivax: polymerase chain reaction amplification artifacts limit the suitability of pvgam1 as a genetic marker. Exp Parasitol 2001; 99:175-9.
15. Gomez JC, McNamara DT, Bockarie MJ, Baird JK, Carlton JM, Zimmerman PA. Identification of a polymorphic Plasmodium vivax microsatellite marker. Am J Trop Med Hyg 2003; 69:377-9.
16. Alam MT, Agarwal R, Sharma YD. Extensive heterozygosity at four microsatellite loci flanking Plasmodium vivax dihydrofolate reductase gene. Mol Biochem Parasitol 2007; 153:178-85.
17. Putaporntip C, Jongwutiwes S, Sakihama N, et al. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci U S A 2002; 99:16348-53.
18. Rayner JC, Huber CS, Feldman D, Ingravallo P, Galinski MR, Barnwell JW. Plasmodium vivax merozoite surface protein PvMSP-3 beta is radically polymorphic through mutation and large insertions and deletions. Infect Genet Evol 2004; 4:309-19.
19. Gomez A, Suarez CF, Martinez P, Saravia C, Patarroyo MA. High polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5). Parasitology 2006; 133:661-72.
20. Sousa TN, Ceravolo IP, Fernandes Fontes CJ, Couto A, Carvalho LH, Brito CF. The pattern of major polymorphisms in the Duffy binding protein ligand domain among Plasmodium vivax isolates from the Brazilian Amazon area. Mol Biochem Parasitol 2006; 146:251-4.
21. Cole-Tobian J, King CL. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol 2003; 127:121-32.
22. Feng X, Carlton JM, Joy DA, et al. Single-nucleotide polymorphisms and genome diversity in Plasmodium vivax. Proc Natl Acad Sci U S A 2003; 100:8502-7.
23. Falk N, Maire N, Sama W, et al. Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg 2006; 74:944-50.
24. Karunaweera ND, Ferreira MU, Munasinghe A, et al. Extensive microsatellite diversity in the human malaria parasite Plasmodium vivax. Gene 2008; 410:105-12.
25. Karunaweera ND, Ferreira MU, Hartl DL, Wirth DF. Fourteen polymorphic microsatellite DNA markers for the human malaria parasite Plasmodium vivax. Molecular Ecology Notes 2006; 7:172-5.
26. Leclerc MC, Durand P, Gauthier C, et al. Meager genetic variability of the human malaria agent Plasmodium vivax. Proc Natl Acad Sci U S A 2004; 101:14455-60.
27. Imwong M, Nair S, Pukrittayakamee S, et al. Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int J Parasitol 2007; 37:1013-22.
28. Marfurt J, Mueller I, Sie A, et al. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 2007; 77:947-54.
29. Gatton ML, Cheng Q. Can estimates of antimalarial efficacy from field studies be improved? Trends Parasitol 2008; 24:68-73.
30. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Amsterdam, the Netherlands: Medicines for Malaria Venture and the World Health Organization, 2008.
31. Bruce MC, Galinski MR, Barnwell JW, et al. Genetic diversity and dynamics of plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. Parasitology 2000; 121:257-72.
32. Cole-Tobian JL, Biasor M, King CL. High complexity of Plasmodium vivax infections in Papua New Guinean children. Am J Trop Med Hyg 2005; 73:626-33.
33. Coatney GR, Cooper WC, Young MD. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J Natl Malar Soc 1950; 9:381-96.